Table 3

Hypertension and hyperlipidaemia medication usage among patients, stratified by body mass index (BMI) category

VariableTotalBMI (kg/m2)
N (%)<2525–29.930–34.935–39.9≥40
All subjects324 199 (100.0%)68 424 (21.1%)121 287 (37.4%)75 199 (23.2%)34 152 (10.5%)25 137 (7.8%)
Hypertension medication120 993 (37.3%)13 345 (19.5%)43 014 (35.5%)33 774 (44.9%)17 219 (50.4%)13 641 (54.3%)
Number of classes of hypertension medications, median (IQR)0 (0–2)0 (0–0)0 (0–2)0 (0–2)1 (0–2)1 (0–2)
Cholesterol-lowering medications83 637 (25.8%)8288 (12.1%)33 802 (27.9%)23 982 (31.9%)10 626 (31.1%)6939 (27.6%)
Statin+second drug
(non-statin)*
8915 (2.7%)646 (0.9%)3586 (3.0%)2698 (3.6%)1264 (3.7%)721 (2.9%)
Statin only69 071 (21.3%)6921 (10.1%)28 068 (23.1%)19 696 (26.2%)8657 (25.3%)5729 (22.8%)
Non-statin drug only5651 (1.7%)721 (1.1%)2148 (1.9%)1588 (1.8%)705 (2.1%)489 (2.1%)
  • All measured associations between the weight classifications and the patient characteristics were statistically significant with a P value<0.0001.

  • *Non-statin cholesterol-lowering medications included bile acid sequestrants, fibrates and other dyslipidemia drugs that comprise a variety of different mechanisms of action.